Agree Realty Corporation

Fundamentals6.0
Price Action6.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • High operating margins
  • Negative free cash flow
  • Low asset turnover

AI
AI Summary

6.0

Agree Realty has transitioned from a steady dividend net-lease REIT into a growth-through-deployment platform, so the investment now hinges on disciplined execution of acquisitions/development (target ~7% cap rates) and near-term financing access rather than being a safe yield play. Key actionable monitorables: quarterly FCF conversion, acquisition cap rates vs. initial underwriting, forward-equity dilution cadence, and leverage metrics (net debt/EBITDA) — any funding dislocation or cap‑rate re‑pricing would materially impair NAV and the dividend.

GrowthOpportunity
ExecutionRisk
Leverage‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • High operating margins
  • Negative free cash flow
  • Low asset turnover

High margins and positive operating cash flow are outweighed by very low asset turnover, heavy capex driving negative free cash flow and thin liquidity, making the dividend and current rich valuation risky. #strong-margins‍

liquidity

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below 21-day
  • Resistance ~82
  • Support 77–79

ADC has pulled back over the last month from a March high near $81.92 to close $76.15, trading below the last month's 21-day average (~$79.8) and testing near-term support around $77–$79 with resistance at ~$82. ‌

pullback
watch
Support Level: $77–$79
Resistance Level: $82

~6.8% decline from $81.92 to $76.15 over the last month, breaking below the last month's 21-day average

Sentiment & News

6.0

Key News Insights:

  • Dividend lift
  • Institutional flows
  • Near‑term readouts

Agree Realty is drawing dividend-focused investor flows and analyst support while antibody‑drug conjugate developers push near‑term clinical readouts and financing moves into mid‑2026.

ADCs

Expect Agree Realty to trade as a defensive, income-focused name while ADC biotech stocks stay catalyst-driven and potentially volatile ahead of mid‑2026 data